Fitzgerald Trae 4

What Happened

• Trae Fitzgerald, Chief Financial Officer of Viemed Healthcare (VMD), reported vesting and settlement activity tied to previously granted restricted stock units (RSUs) and phantom share awards. On Jan 17, 2026, vested awards were settled: 3,132 shares were withheld by the issuer to satisfy tax obligations (reported as a disposition, $7.33/share, $22,958) and 2,397 phantom shares were cash‑settled/returned to the issuer for $7.33/share ($17,570). The filing also shows conversion/settlement activity for 11,987 derivative units (9,590 + 2,397) related to those vestings. On Jan 19, 2026 Fitzgerald received new awards: 46,662 phantom shares and 11,666 RSUs (both reported as $0 value and vesting in three equal annual installments).

Key Details

• Transaction dates: Vesting/settlement on Jan 17, 2026; new grants reported Jan 19, 2026. Filing date: Jan 21, 2026.
• Price(s) / cash amounts: Tax withholding of 3,132 shares at $7.33 = $22,958; cash settlement/disposition of 2,397 phantom shares at $7.33 = $17,570. Total cash value reported ≈ $40,528.
• Type of transactions: Vesting/settlement of RSUs (F = tax withholding) and cash‑settlement of phantom shares (M/D per footnotes); new grants awarded (A) on Jan 19, 2026.
• Shares owned after the transactions: Not specified in the itemized data provided in the filing summary.
• Notable footnotes: F2 indicates shares were withheld to cover taxes from RSU vesting; F4 explains phantom shares are cash‑settled (economic equivalent of common shares) and their settlement is reported as a conversion/acquisition and simultaneous disposition back to the company; F5–F9 describe grant dates and 3‑year vesting schedules for the awards.

Context

• These transactions reflect routine compensation vesting (RSUs and phantom share units) and cash settlement rather than a classic open‑market sale or purchase. The phantom shares were settled for cash (a cashless-like outcome) rather than the insider keeping and selling open‑market shares. Such events are common around scheduled vesting dates and do not, by themselves, imply a buy/sell signal about management’s view of the stock.